



DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 76-238

Food and Drug Administration
Rockville MD 20857

APR 22 2004

Barr Laboratories, Inc.
Attention: Nicholas C. Tantillo
2 Quaker Road
P.O. Box 2900
Pomona, NY 10970-0519

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated September 17, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Balziva™-28 Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4 mg/0.035 mg, respectively), packaged in a 28-day cycle regimen.

Reference is also made to your amendments dated September 12, and October 23, 2003; and March 30, 2004.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Balziva™-28 Tablets to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Ovcon-35®-28 Tablets, of Warner Chilcott, Inc.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.


Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FDA 2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Gary Buehler" with a stylized flourish at the end.

Gary Buehler

Director

Office of Generic Drugs

Center for Drug Evaluation and Research